Product information and disease descriptionPlace of product in therapyDisease description
Natural history, survival, and mortality
11 evidence topics · 14 sources
Natural history: progression from ocular to generalized disease
“In addition, up to 80% of patients with ocular onset will go on to develop generalized symptoms, usually within two years of disease onset” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A recent population-based study conducted by the Mayo Clinic found that 51% of patients presented with ocular onset, and 55% of these developed generalized symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the remaining, 90% will continue to have ocular manifestations only.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hence, ocular MG is defined by isolated extra-ocular involvement for a period of ≥2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: severity peaks early, and exacerbations recur
“Between 1940 and 2000 a total of 1976 patients with myasthenia gravis (MG) were studied.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The most severe level of weakness and high mortality occurred during the first 1 to 2 years of the disease, after which many patients experienced improvement.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Natural history: spontaneous remission
“Spontaneous remissions for different lengths of time may occur in the course of adult-onset MG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In an earlier study conducted before the widespread use of steroids and other immunosuppressants, approximately one fourth of the patients had a complete or near complete spontaneous remission, lasting an average of 4.6 years and up to 17 years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Half of the remissions occurred during the first year after onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: global systematic review
“showing a mean MR of 1.4 (95% CI: 0.8–2.1; range: 0.5–3.5) cases per million person-years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No trend was observed for MR over the years” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: United States hospitalizations, 2010 to 2019
“Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality among patients aged 65 years or older was higher compared with that in all patients, averaging 5.0% across each of the study years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: United States hospitalizations, 2000 to 2005
“The overall in-hospital mortality rate was 2.2%, being higher in MG crisis (4.47%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Older age and respiratory failure were the predictors of death, with adjusted odds ratios of 9.28 (95% confidence interval [CI], 3.31, 26.0) and 3.58 (95% CI, 2.01, 6.38).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality and survival: United States Medicare beneficiaries aged 65 years and older
“All-cause mortality among MG beneficiaries was stable from 6.26 deaths per 100 PYs in 2006–2007 to 5.67 in 2018–2019 (p = 0.18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cohorts of 6024 incident MG and 30,083 control beneficiaries were Included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mortality rate was higher in the MG cohort compared to controls (66.8 vs. 57.1 per 1000-person-year, p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“After adjusting for time-varying CCI, no significant difference in survival was observed between two cohorts (adjusted hazard ratio 1.09 [0.87-1.36], p = 0.47).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen percent of deaths in the MG cohort were attributed to MG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Compared to the non-MG cohort, mortality rates (per 1000-person-year) specific to infections were higher among the MG cohort (2.0 vs. 1.2) while malignancies and dementia-specific mortality rates were lower (10.3 vs. 12.5 and 4.7 vs. 7.2), all p < 0.01.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Denmark nationwide cohort, 1985 to 2020
“Our cohort encompassed 2,110 patients (50.2% female) and 21,100 from the general population, with 77.3% aged younger than 75 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Short-term cumulative mortality was 4.8% in patients with MG and 2.6% in the general population, yielding a HR of 1.8 (95% CI 1.5-2.3). Long-term mortality was 1.3 (95% CI 1.1-1.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Comorbidity-adjusted analyses decreased short-term mortality (HR 1.6, 95% CI 1.3-2.0), and long-term mortality aligned with the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Taiwan, generalized myasthenia gravis, 2009 to 2019
Survival: Ontario, Canada, with and without myasthenic crisis
“Myasthenic crisis occurred in 8.9% of individuals over the study, with a post‐diagnosis incidence rate of 2.6 per 100 person‐years and 30‐day mortality of 28.1%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“5‐year overall survival was 75%, declining to 39% among those with crisis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mortality: Israel, tertiary center cohort, 2000 to 2023
“Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality was significantly higher than control groups (p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intubations during myasthenic crisis were linked to higher mortality (p = 0.002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote